Medeon Biodesign

Medeon Biodesign EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medeon Biodesign (6499.TWO) as of Nov 5, 2026 is -722.45 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -862.36 M TWD — a change of -16.22% (higher).

EBITDA

-722.45 MTWD

YoY

-16.22%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medeon Biodesign is 2025 -722.45 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medeon Biodesign was 2024 -862.36 M TWD. It decreases by -16.22% higher compared to the previous year.

The Medeon Biodesign EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
201.45 M TWD
Jan 1, 2019
-231.06 M TWD
Jan 1, 2020
-96.97 M TWD
Jan 1, 2021
-495.59 M TWD
Jan 1, 2022
-487.84 M TWD
Jan 1, 2023
-829.49 M TWD
Jan 1, 2024
-862.36 M TWD
Jan 1, 2025
-722.45 M TWD
The Medeon Biodesign EBITDA history
YEAREBITDAYoY
-722.45 MTWD-16.22%
-862.36 MTWD+3.96%
-829.49 MTWD+70.03%
-487.84 MTWD-1.56%
-495.59 MTWD+411.10%
-96.97 MTWD-58.04%
-231.06 MTWD-214.70%
201.45 MTWD-181.17%
-248.18 MTWD+11.30%
-222.99 MTWD+23.63%
-180.37 MTWD+106.95%
-87.15 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medeon Biodesign Stock analysis

What does Medeon Biodesign do? Medeon Biodesign Inc, headquartered in Taipei City, Taiwan, develops, manufactures, and sells medical equipment. Listed on 11 December 2014, the company specializes in medical apparatus and instruments for laparoscopic and cardiac catheter minimally invasive surgeries. Its products are distributed domestically and internationally, serving the Health Care sector with innovative surgical solutions. Medeon Biodesign is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medeon Biodesign stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medeon Biodesign is -722.45 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medeon Biodesign changed from -862.36 M TWD to -722.45 M TWD, representing a -16.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Medeon Biodesign since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Medeon Biodesign historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Medeon Biodesign

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Medeon Biodesign